Cat. No. 5590
Chemical Name: 4-[4-[(Dimethylamino)methyl]-2,5-di
Biological ActivityPotent and selective BRD9 and BRD7 inhibitor (Kd values are 14 and 239 nM, respectively). Exhibits selectivity for BRD9/7 over 48 other bromodomains, 324 kinases and 55 GPCRs. Inhibits proliferation of AML cell lines in vitro and reduces AML tumor xenograft growth in vivo. Cell permeable and orally active.
Licensing InformationThis probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the BI 9564 probe summary on the SGC website.
External Portal InformationChemicalprobes.org is a portal that offers independent guidance on the selection and/or application of small molecules for research. The use of BI-9564 is reviewed on the chemical probes website.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Karim and Schönbrunn (2016) An Advanced Tool To Interrogate BRD9. J.Med.Chem. 59 4459. PMID: 27120693.
Martin et al (2016) Structure-based design of an in vivo active selective BRD9 inhibitor J.Med.Chem. 59 4462. PMID: 26914985.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses BI 9564 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: BI 9564, supplier, BI9564, BRD9, BRD7, potent, selective, inhibitors, inhibits, bromodomains, orally, active, Tocris Bioscience, Bromodomain Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent BRD9/7 inhibitorBAY 299
Potent and selective BRD1 and TAF1 inhibitorNVS-CECR2-1
Potent and selective inhibitor of cat eye syndrome chromosome region, candidate 2 (CECR2)NI 42
High affinity BRPF inhibitor
Tocris has a collaboration with the Structural Genomics Consortium (SGC) to provide the latest high quality epigenetics probes.